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Abstract
Adverse drug reactions (ADR), also known as side-effects, are complex undesired physiologic phenomena observed
secondary to the administration of pharmaceuticals. Several phenomena underlie the emergence of each ADR; however, a
dominant factor is the drug’s ability to modulate one or more biological pathways. Understanding the biological processes
behind the occurrence of ADRs would lead to the development of safer and more effective drugs. At present, no method
exists to discover these ADR-pathway associations. In this paper we introduce a computational framework for identifying a
subset of these associations based on the assumption that drugs capable of modulating the same pathway may induce
similar ADRs. Our model exploits multiple information resources. First, we utilize a publicly available dataset pairing drugs
with their observed ADRs. Second, we identify putative protein targets for each drug using the protein structure database
and in-silico virtual docking. Third, we label each protein target with its known involvement in one or more biological
pathways. Finally, the relationships among these information sources are mined using multiple stages of logistic-regression
while controlling for over-fitting and multiple-hypothesis testing. As proof-of-concept, we examined a dataset of 506 ADRs,
730 drugs, and 830 human protein targets. Our method yielded 185 ADR-pathway associations of which 45 were selected to
undergo a manual literature review. We found 32 associations to be supported by the scientific literature.
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Introduction
Adverse drug reactions (ADRs), often informally referred to as
side-effects, are rare complex physiologic phenomena that involve
various molecular processes [1]. Understanding these processes
may greatly impact the fields of drug discovery and personalized
medicine through the development of safer drugs, the discovery of
new bio-markers, and the identification of new uses for existing
drugs. Factors such as the patient’s genetic polymorphism,
personal history, and environmental exposure as well as drug
kinetics, treatment dosage, and molecular metabolism often
contribute to ADRs through a direct or indirect perturbation of
biological pathways [2]. While some ADRs result from the desired
interaction between drugs and their primary targets, in the
majority of cases these effects are caused by promiscuous off-target
binding of the drug [3].
Several recent studies have investigated the promiscuous
relationship between drugs, targets, and observed ADRs (in this
manuscript we will use the terms ADR and side-effect inter-
changeably). Fliri et al. studied the relationships between side-
effect profiles of drugs, their chemical structure, and the organism
response. They clustered drugs according to their side-effect
profiles and clustered side-effects according to the biological
systems of their associated drugs (e.g., immune system) thereby
linking side-effects and interaction patterns of drugs [4]. In a
follow-up study they explored the above relations as a mechanism
for predicting sets of side-effects for new drug candidates [5]. Their
findings reinforce the hypothesis that structurally similar drugs are
likely to induce similar side-effects. Campillos et al. identified
alternative targets for known drugs under the hypothesis that
structurally similar drugs sharing similar side-effect profiles were
also likely to share targets [6]. Keiser et al. analyzed the
relationship between protein targets and their ligands using a
ligand-based similarity metric that groups together seemingly
unrelated proteins [7]. In another study, the same group
constructed a model to identify alternative drug labels (or
functions) for known drugs by comparing their binding promis-
cuity [8]. They explored the similarity between drugs and native
ligands as an indication for possible binding promiscuity and the
use of this information to suggest alternative drug targets. In
general, the studies mentioned above utilized ADR profiles as a
feature set or fingerprint to predict new drug targets. In each case,
the biological process underlying the ADR remained hidden.
Recently, Xie et al. [9] have used virtual docking to study ADRs
related to the cholesteryl ester transfer protein (CETP) and
identified possible off-target interactions for a set of CETP
inhibitors. Their method uses a known 3D protein structure of
the primary target to characterize the binding site of the drugs.
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proteins having similar binding sites. Possible interactions between
the resulting set of proteins and the drugs are then studied using
virtual docking. In a subsequent work, Durrant et al. [10]
augmented that method by adding an evolutionary model to
account for protein sequence homology. A substantial limitation of
these two approaches is their reliance on the availability of a 3D
structure of the primary target. Thus, this method may not be
feasible when studying many popular drug targets [11] for which
no 3D model yet exists. An approach that does not require any
structural knowledge of the primary target was suggested by Yang
et al. [12]. In their work, they used virtual docking to propose
possible interactions between a set of 845 proteins and a set of 162
drugs all known to induce at least one of four ADRs. Similar to
Xie et al., they aimed to identify off-target proteins involved in the
appearance of ADRs under the hypothesis that drugs causing the
same ADR may target the same proteins. Scheiber et al. [13]
analyzed the structural similarity of drugs associated with similar
ADRs and identified common chemical sub-structures that may be
involved in the induction of ADRs. In a related work from the
same group [14], cheminformatics target prediction methods were
used to identify potential off-targets for drugs that share the same
ADRs. Then, pathways were related to ADRs based on direct
mapping between predicted targets and pathways.
In this work, we developed a computational framework for
proposing associations between the ADRs of clinically approved
drugs and the modulation of underlying biological pathways. In
contrast to the work of Xie et al. [9] and Yang et al. [12], our
model exploits the assumption that drugs capable of modulating
similar pathways may have similar ADR profiles. Under this
assumption, an ADR may be associated with a pathway when
structurally different drugs, known to induce the same ADR, bind
proteins in the same pathway. Using pathway information to
connect between ADRs and predicted protein-drug interactions
provides two advantages. First, it allows our model to observe cases
in which different drugs modulate the same protein target and
second, it allows us to identify cases in which the modulation of a
pathway via different proteins affects the same biological process.
Furthermore, proteins that participate in several pathways can
implicate multiple biological processes with a single ADR. We
reveal ADR-pathway associations by exploiting three knowledge
bases: (i) the SIDER database of ADR profiles for drugs [15], (ii)
the KEGG database of biological pathway annotation [16], and
(iii) the PDB database of protein structures [17]. Each drug is
mapped to several potentially affected pathways by docking the
ligand into a set of pathway annotated human proteins.
The comparison of docking profiles for different drugs producing
the same ADR allows us to exploit both evidence of binding and
non-binding in building a consistent, minimal hypothesis. For
example, consider the case where two drugs produce the same
ADR. If only one of the two drugs is predicted to interact with
pathway X, then it is less likely that pathway X is solely responsible
for the ADR. The drug that does not interact with pathway X
provides evidence that disrupting the pathway is not necessary
(although it may be sufficient). We refer to the information provided
by this non-interacting prediction as negative evidence. The
proposed interactions between drugs and pathways along with the
known co-occurrence of drugs and ADRs are then used to learn
associations between pathways and ADRs. Our method demon-
stratestheabilitytodrawcorrelationsbetweenADRsand pathways,
despite the virtualdocking limitations,andthe incomplete catalog of
biological processes. Future improvements in virtual docking
algorithms and expansion of our knowledge of biological processes
should make our method more effective.
Results
We developed a computational model that associates ADRs
with biological pathways. The model is summarized in this
paragraph (full details appear in the Methods section). We used the
empirically observed relations between drugs and ADRs, the
mapping of target proteins into pathways, and the virtual
normalized docking results of drugs onto experimentally deter-
mined human protein structures to construct a graphical
representation of these relations (Figure 1). The current study
utilized 730 small-molecule clinically-approved drugs [15] and 830
target proteins with solved structures [17]. The protein targets
were associated with 176 human related pathways extracted from
the KEGG database [16]. The drugs were associated with 506
ADRs extracted from the SIDER database [15]. Our computa-
tional model learns a set of connections from ADRs to pathways
consistent with the observed drug-ADR relations. We note that for
some drugs, the ADRs listed in the SIDER database are not
traditional ADRs. For example, viral and bacterial infections, such
as herpes and tuberculosis, are listed as ADRs but clearly, do not
result from direct perturbations of a biological pathway. These
ADRs reflect the observations of viral/bacterial infections while
patients were under the administration of corresponding drugs.
Viral infections may be listed as ADR if a drug perturbs some
biological mechanisms and, as a result, increases vulnerability to
viral infections. Alternatively, an ADR may not reflect a causative
relation. For example, cancer or HIV patients having a stressed
immune system, may suffer from increased vulnerability to
infections. Consequently, cancer or HIV related drugs may be
associated with infectious related ADRs without any causative
underlying mechanism. In the results below we demonstrate
several such examples. For clarity, we will refer to these biological
pathway-ADR associations as simply associations. The learning of
these associations employed a 2-phase logistic-regression model
with L1-regularization and feature selection [18,19]. This method
was designed to avoid overfitting the small number of input
samples by using techniques that heavily penalize complex models.
As a result, the model identifies a small informative set of
associations for which there is the most evidence. Utilizing a
multiple testing correction with a false-discovery rate of 2% our
model identified a set of 185 associations worthy of further
investigation (Figure 2 and Table S3). These 185 associations
involve 90 pathways and 121 ADRs and represent an extremely
small fraction of the 89,056 possible pathway-ADR associations
(176 pathways and 506 ADRs).
Analysis of the inferred associations
Validating associations in the predicted set is a challenging task
(see the Discussion). In this work, we manually reviewed relevant
scientific literature for existent evidence of correctness of our
predicted associations. Clearly, the most fundamental limitation of
this approach is that we can only support associations already
discovered while novel associations suggested by our model will
not have any direct support in the literature. In order to facilitate
the process of a manual literature review, we first discarded
associations for which relevant literature is sparse. In the filtering
process, we analyzed the 185 inferred associations using associative
text-mining over the biomedical literature. Similar to Fliri et al. [5]
we used the frequency at which the association’s terms appear in
scientific publications as supporting evidence of correctness. Prior
to performing each search, the terms of the association were
expanded to include equivalent MeSH terms (http://www.nlm.
nih.gov/mesh). Then, for every association we performed a
PubMed search (http://www.ncbi.nlm.nih.gov/pubmed) for en-
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pathway and the ADR). These associations were ranked by the
number of hits and the highly ranked associations were chosen to
undergo a manual literature review. While this text-mining
approach has been used in previous studies [5,20], the technique
does have some limitations. First, it is more likely to return a hit
when the two phrases are directly related. Second, the method can
only validate previously observed associations; consequently, the
inability to validate an association does not imply that it is false, it
may simply be unknown (see the Discussion section). Despite these
caveats, text mining can provide evidence in support of identified
associations. Of the 185 associations identified by our model, 45
exceeded our threshold of having at least 5 PubMed hits and were
selected for manual review. After manual examination of the
relevant literature, we propose that 22 associations are supported
and 10 have slightly less support but remain worthy of further
investigation (Table 1). All drug names related to the validated
associations appears in Table S9. The full set of relations between
drugs, proteins, pathways, and ADRs, is provided in File S1 as a
Cytoscape [21] file. We stress that this PubMed-based filtering was
only used to facilitate a thorough manual literature review. By
selecting a subset of associations that had sufficient annotations in
the literature we able to focus on those associations more likely to
be valid. Nevertheless, associations not passing the 5-hit threshold
may still be correct. For example, the associations of skin nodule
and the GAG degradation pathway or aseptic necrosis and the
Type-II diabetes pathway did not pass the 5-hit threshold yet were
supported by scientific evidences. Another important clarification
is that the identification of an association does not, of course,
necessarily imply causality. A causal relation may be partial such
that the inferred pathway is involved in the occurrence of the ADR
but is not the sole cause for it. Also, since the ADR data is simply a
record of ADR observations coincident with the administration of
drugs, non-causative relations may exist in the data and may be
found by our model. For example, a pathway may characterize a
group of patients for which the ADR is likely to be observed (see
the association of hernia with the prostate-cancer pathway below).
In the remainder of this section, we discuss some of the
associations identified by our method and supported by the
scientific literature. For brevity, we list only a limited set of
supporting references for each association below. The complete set
of references can be found in Table S1 and File S2.
ADRs associated with the glycosaminoglycan degradation
pathway. Glycosaminoclycan (GAG) proteins are abundant in
the extracellular matrix and cell membrane and are the first host
macromolecules encountered by most infectious agents [22]. Our
model associates eight ADRs with the GAG degradation pathway
from which six were supported in the literature. These include
three ADRs of bacterial or viral infection. Tuberculosis (TB) is a
bacterial infection that most commonly affects the respiratory
system [23]. GAG proteins have shown to be involved in bacterial
and viral infection, including TB, by exploiting GAG proteins to
mediate the attachment to target cells [22,23]. Interestingly, there
is also an association between the herpes zoster virus (HZV) and
Figure 1. An illustration of the inference method. Drug-pathway interactions are inferred from the results of protein-ligand docking. The KEGG
database [16] is used to map proteins to biological pathways. The SIDER database [15] associates drugs with their observed ADRs. In the docking
phase each drug (orange star) is docked against each protein (purple diamond) producing a set of docking results (green triangles). Then, two phases
of logistic regression are used to select those associations that are statistically significant. In phase-I, logistic regression with L1-regularization is used
to infer a set of informative connections between pathways (blue circles) and ADRs (red squares). In phase-II, a second logistic-regression model
selects the associations selected from phase-I that are statistically significant under multiple hypothesis correction (see Methods section).
doi:10.1371/journal.pone.0012063.g001
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strated a connection between viral infection, particularly herpes,
and GAG proteins [24,25]. Furthermore, inspection of the
suggested interactions between drugs associated with TB and
HZV and proteins in the GAG pathway showed that in both TB
and HZV infections a single beta-glucuronidase lysosomal
enzyme (1BHG) plays a central role (Figure 3). Our model also
suggests the association between meningitis infection and the
heparan sulfate biosynthesis pathway. Heparan sulfate is a
member of the GAG family and is known to be involved in
bacterial and viral infection [26]. Thus, for reasons similar to the
above, perturbation of the heparan sulfate biosynthesis may
increase the risk of meningitis. These three infection related
ADRs present an interesting case. Each of the three infection
related ADRs is supported by a relatively independent set of
drugs. Of the 27 drugs predicted to interact with the GAG
degradation pathway, 23 are associated with only one of the three
infection related ADRs (Figure S1). This suggests that the three
associations were independently inferred.
Other ADRs associated with the GAG degradation pathway are
wound dehiscence, amylase increased, and skin nodules. GAG
proteins are involved in wound healing and thus may be involved
in the occurrence of wound dehiscence [27]. Elevated serum
amylase level is one of the indicators of acute pancreatitis [28], an
inflammation of the pancreas that has been associated with the
GAG pathway [29]. Skin nodules are associated with abnormal
level of GAG proteins and particularly heparan sulphate
proteoglycan [30,31].
ADRs associated with the nicotinate and nicotinamide
metabolism pathway. The nicotinate and nicotinamide
(NAD) pathway is involved in the synthesis, utilization and/or
degradation of nicotinate and nicotinamide. Our model associates
eight ADRs with the NAD pathway from which fibrosis, cirrhosis,
and ascites were supported in the literature (Table S1).
Figure 2. An illustration of the network of pathway-ADR associations inferred by our model. Side-effects are represented as red squares
and pathways as blue circles. The full list of 185 associations is available at Table S3. The 22 associations most strongly supported by the literature are
circled. Pathways are colored by their KEGG categories.
doi:10.1371/journal.pone.0012063.g002
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the cumulation of excessive collagen in an organ and the
formation of scar tissue [32], cirrhosis is an advanced form of
liver fibrosis and is characterized by formation of a fibrous scar
[33], and ascites is the cumulation of excessive fluid in the
abdominal cavity and has been shown to be associated with
cirrhosis [34,35]. Similar to the GAG degradation pathway
example, each of the three fibrosis related ADRs were supported
by a relatively independent set of drugs (Figure S3).
ADRs associated with the type-II diabetes mellitus
pathway. Type-II diabetes mellitus (diabetes hereafter) is a
disorder of insulin resistance or insulin deficiency characterized by
high serum glucose levels [36]. Our model associates four ADRs
with the diabetes pathway: osteoporosis, aseptic necrosis, alkalosis,
and ptosis, all supported in the literature (Table S1). Particularly
interesting are the first two associations. Osteoporosis is a bone
disorder characterized by an increased risk of fractures due to a
reduction in the bone density [37]. The relation between
osteoporosis and diabetes have been established in several
studies and particularly, diabetic osteopathy, an increased
fracture risk in diabetes patients [38,39]. Inspecting the
Anatomical Therapeutic Chemical classification [40] of the
osteoporosis related drugs showed that 8 drugs were classified as
corticosteroids, a class of drugs that have been associated with both
steroid-induced osteoporosis and diabetes [41]. Aseptic necrosis
(AN) is a disease characterized by the death of cells in bones due to
lack of blood circulation [42]. While fewer indications of possible
connection between diabetes and AN appear in the literature, its
relation to osteoporosis provides support to this association.
Furthermore, an analysis of the drugs associated with
osteoporosis and AN showed that most of them were associated
with only one of the ADRs, thereby suggesting a rather
independent inference of these two related bone disease (Figure
S2).
Hernia – Prostate cancer pathway. A hernia is a
protrusion of a tissue or part of an organ through the cavity that
normally contains it. The prostate cancer pathway mainly
characterizes key molecular alterations in prostate-cancer cells
implicating carcinogen defenses, growth-factor-signaling path-
ways, and androgens [16]. The occurrence of inguinal hernia is
a common phenomenon after radical retropubic prostatectomy
(the removal of the prostate gland) [43,44]. While our model
suggests a connection between hernia and prostate cancer it is
unlikely that perturbations of the prostate related pathways will
result in a hernia. This is a demonstration of a non-causative
association. A plausible explanation for this association is that our
data includes prostate-related drugs that list hernia as an ADR.
Indeed, there are four such drugs (Figure 4) that all list prostate-
related disease as their therapeutic indication [15] and are
suggested by virtual docking to interact with prostate cancer
related proteins. Since a hernia may occur secondary to surgery, it
is likely that the ADR hernia was simply reported as an observed
phenotype for patients treated with prostate cancer related
drugs.
Parkinson’s disease – Pyruvate metabolism pathway.
Parkinson’s disease (PD) is a progressive neurological disorder
characterized by a large number of motor and non-motor features
[45]. Increasing evidence indicates that oxidative stress may play a
crucial role in the pathogenesis of PD and that pyruvate
deficiency, among other anti-oxidant agents, is significantly
involved [46,47]. Our model suggests 33 drugs associated with
PD to interact with 15 proteins from the pyruvate metabolism
pathway (Figure 5) out of which 23 drugs are nervous-system
agents (Table S2). The promiscuity of these drugs is supported by
the fact that 19 of 23 are psychoactive drugs which are well known
for their binding promiscuity [47,48].
Melanoma – Hedgehog signaling pathway. Melanoma is a
malignant tumor of melanocytes. The Hedgehog signaling
pathway plays important roles in determining cell fate, pattern
formation, proliferation, and differentiation. Alteration of the
pathway has been implicated in a number of human cancers,
including melanoma [49,50].
Breast cancer – Non-homologous end-joining pathway.
Non-homologous end-joining (NHEJ) is one of the major pathways
involved in repairing double-strand breaks (DSB) in DNA.
Polymorphisms in NHEJ genes have been shown to be
associated with breast cancer [51,52]. The role of breast cancer
related genes, BRCA1 and BRCA2, in the NHEJ pathway
suggests that the mechanisms involved in DNA DSB repair are of
particularly important during breast tumorigenesis [53].
Table 1. Associations supported by the literature.
Side-effects Pathways
Cerebral infarction Alzheimer’s disease
Osteoporosis Type II diabetes mellitus
Lymphoma Retinol metabolism
Hernia Prostate cancer
Parkinson’s Pyruvate metabolism
Breast cancer Non-homologous end-joining
Pelvic pain Cell cycle
Fibrosis Nicotinate and nicotinamide metabolism
Hepatic encephalopathy Thiamine metabolism
Melanoma Hedgehog signaling pathway
Prostatitis Pathogenic Escherichia coli infection
Alkalosis Type II diabetes mellitus
Stria Heparan sulfate biosynthesis
Tuberculosis Glycosaminoglycan degradation
Herpes zoster Glycosaminoglycan degradation
Cirrhosis Nicotinate and nicotinamide metabolism
Ascites Nicotinate and nicotinamide metabolism
Meningitis Heparan sulfate biosynthesis
Wound dehiscence Glycosaminoglycan degradation
Amylase increased Glycosaminoglycan degradation
Fibrosis Keratan sulfate biosynthesis
Ptosis Type II diabetes mellitus
Aseptic meningitis Systemic lupus erythematosus
Lymphoma Heparan sulfate biosynthesis
Skin carcinoma Lysosome
Alkalosis Biosynthesis of unsaturated fatty acids
Hyperparathyroidism Autoimmune thyroid disease
Fibrosis Metabolism of xenobiotics by cytochrome P450
Vitamin-D deficiency Autoimmune thyroid disease
Skin carcinoma Androgen and estrogen metabolism
Rigmentary retinopathy Sulfur metabolism
ESR increased Parkinson’s disease
The 32 associations supported by the literature. (Top) The 22 associations with
stronger support. (Bottom) The 10 associations with moderate support (see
Table S1 for a full reference list).
doi:10.1371/journal.pone.0012063.t001
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12063Figure 3. GAG-related ADRs. The illustration represents proteins as green triangles, drugs as orange diamonds, ADRs as red squares, and
pathways as blue circles. Protein-ligand interactions as predicted by virtual docking are represented as green dashed lines. Inferred pathway-ADR
associations are represented by purple dashed lines. Observed ADR-drug pairs come from the SIDER database and are represented by solid brown
lines. Finally, KEGG labels connect proteins to biological pathways and are represented as blue lines.
doi:10.1371/journal.pone.0012063.g003
Figure 4. Relations between hernia and the prostate cancer pathway. An illustration of the model’s suggested interactions between drugs
coincident with hernia and proteins belong to the prostate cancer pathway. This is an example of a non-causative association where drugs listing
prostate-related disease as their therapeutic indication indeed interact with proteins in the prostate cancer pathway. Since patients suffering from
prostate cancer are likely to experience a post-operative hernia, an association between hernia and prostate cancer emerges. Node and edge
representation is the same as Figure 3.
doi:10.1371/journal.pone.0012063.g004
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The associations suggested by our model were based on its
ability to identify meaningful correlations in imperfect virtual
docking results. Of course, validated associations could have been
discovered randomly, independent of the information provided by
the docking results and the structure of the biological network. In
order to estimate the accuracy of the docking, to demonstrate that
the docking results convey useful information, and to evaluate the
likelihood of discovering true associations by chance, we
preformed the following sets of experiments.
Ranking benchmarks. In order to test how well the docking
algorithm ranks active ligands we examined the ranking
performance for the 16 DrugBank [54] drug-target pairs that
also exist in our dataset. For each ligand, we tested how well the
docking algorithm was able to rank drugs when docked into their
known targets. In 7 cases, the known interacting drug was ranked
higher than one standard deviation from the mean score (z-score
greater than one, see Table S8). The theoretical probability of
observing such an event (drawing 7 or more numbers greater than
1 from a normal distribution in 16 trials) is less than 0.0016. As a
second test, we used the DUD benchmark [55] to asses the ability
of the docking algorithm to rank active ligands. DUD is considered
the gold standard for benchmarking the ranking provided by
virtual docking algorithms. We measure ranking success using the
area under the curve (AUC) of the decoys verses actives ranking.
Using the DUD benchmark, the docking algorithm achieved a
median AUC value of 0.8717. In 15 out of 35 DUD test cases, the
AUC was greater than 0.9 (See Figure S4).
Randomized control for docking results. We assessed the
information content of the virtual docking by performing 1000
randomized trials. In each trial, we randomly shuffled the
mapping between the drugs and their docking results (note that
this is equivalent to shuffling the mapping between drugs to ADRs)
and used this random data as the input for our model. A
comparison of the number of returned associations by our
predictive model (185) to the distribution of returned
associations from the 100 randomized experiments (mean 116.47
and standard deviation 18.45) showed that there was less than
0.01% chance our number of results were drawn from random
unstructured data. This implies that there is structure to the virtual
screening data.
Randomized control for associations. We demonstrated
the ability of our model to retrieve associations that are supported
by the literature. We evaluated the significance of the identified
associations using a randomized control. Ideally, we could
randomize the input data, use our algorithm to predict
associations, and then assess the correctness of each association
via an expert. Performing 100 randomization trials would require
the infeasible task of manually evaluating up to 18,500
associations. Instead, we determined if the number of PubMed
supported hits in our results (45 out of 185) was statistically
different from the expected number of supported associations
when drawn at random. We emphasize, that in this experiment we
use the PubMed hit count in a different manner than described
before. Initially, we used the PubMed hit count to reduce the
number of associations which underwent a manual literature
review while in this case, we use it as a substitution for the actual
manual review. All terms in the random associations were drawn
only from those that appeared in the 185 predicted associations (90
pathways and 121 ADRs). As before, for each random association
Figure 5. Relations between Parkinson’s disease and the pyruvate metabolism pathway. An illustration of the model’s suggested
interactions between drugs coincident with Parkinson’s disease and proteins belonging to the pyruvate metabolism pathway. Node and edge
representation is the same as Figure 3.
doi:10.1371/journal.pone.0012063.g005
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PubMed. The expected distribution of random associations with at
least 5 PubMed hits (mean 37.79, standard-deviation 4.85)
suggests a less than 5% chance that our results were drawn from
the random data distribution.
Discussion
The encouraging results presented in this manuscript come
despite several limitations. Our method utilizes computational
predictions of protein-ligand binding across the human proteome.
This requirement means our results are affected by three factors,
the availability of protein structures, the accuracy of virtual
docking, and the complicating effects of genetic polymorphisms.
Although the largest possible set of publicly available human
protein structures contains only 830 macromolecules, we were able
to identify significant pathway-ADR associations that involve the
selected proteins. Virtual docking still struggles with computing
true binding energies; however, our model relies on the easier task
of separating active binders from decoys. Many docking
algorithms, including the eHiTS software utilized in this work
[56], are well suited for this ranking task (See Figure S4). Finally,
although genetic polymorphisms play an important role in ADRs,
we propose that in many cases docking into a wild-type protein
and a genetic variant may show grossly similar results. Further-
more, the effects of a genetic variation may be indirect where an
ADR emerges secondary to the interaction of a variant protein
and a ligand perturbed wild type protein. In this case, our method
does not require docking to the genetic variant. The above
limitations restrict our list of associations from being complete; but,
there are several interesting associations among those identified.
Many problems in machine learning are difficult because they
utilize a small number of training samples to fit a large number of
features. In our work, it is difficult to identify pathway-ADR
associations using the small number of ADRs observed for each
drug. In order to adequately deal with a modest set of positive
examples, our model utilizes two phases of logistic-regression
(Figure 1). In the first phase we use L1-regularization [19] to select
an initial set of associations. An L1-penalty term is commonly used
in continuous model selection to identify a small set of informative
features. L1-regularization reduces the risk of over-fitting by
biasing the feature weights towards zero, thereby only allowing
associations with strong evidence to have non-zero weights [18].
Regularization of this type is particularly important when the
number of possible features exceeds the number of observations.
In the second phase, we perform a traditional logistic regression
using the features selected in phase one. Using the forward-
selection backward-elimination algorithm, the AIC model selec-
tion criteria, and a multiple-hypothesis correction we reduce the
number of features to a set that remains statistically significant.
Experimentally validating associations between ADRs and
pathways is a challenging task since true validation is likely to
require in-vivo experiments similar to clinical trails of drug
candidates. The predicted associations fall into three classes: true-
positive (TP), false-positive (FP), and false-false-positive (FFP). TPs
are associations identified by our model, are inherently true, and
are known to be true. FPs are associations identified by our model
yet are inherently false. FFPs are associations identified by our
model and are inherently true, but are as yet unknown to the
scientific field and may therefore be misinterpreted as false. While
one long range aim of our work is to reveal unknown associations
(FFP), by definition it is impossible to validate FFPs without
conducting additional experiments. Although our current method
is unable to validate FFPs, our use of associative text-mining and
manual evaluation allows us to support 32 (of 185) associations as
likely TPs.
The aim of this manuscript is to introduce a computational
framework for identifying pathway-ADR associations. Our
approach is based on predicting the targets of a drug’s
promiscuous binding using a structural model and then connecting
these interactions with biological pathways. Associations are
determined using a statistically grounded approach to inference.
The initial results presented in this manuscript are promising and
we envision that hypotheses generated by our model may guide
future research.
Methods
Preparation of data sets
Drugs. A list of drugs and their corresponding ADRs was
obtained from the SIDER database [15]. Structural models of all
drugs were retrieved from the PubChem database (http://
pubchem.ncbi.nlm.nih.gov) using PubChem’s compound ID
(CID). If no corresponding structure was found in the database,
a 3D model was generated with OpenBabel [57] using the drug’s
SMILES string [58]. In order to increase the likelihood of
successful docking, ligands were filtered by molecular weight and
flexibility. We removed drugs which had: (i) a molecular weight
outside the range of 100–800 Daltons or (ii) 10 or more rotational
bonds. This filtering step yields 730 drugs most compatible with
virtual docking (Table S7).
Protein Targets. The structures of protein targets satisfying
the following criteria were obtained from the Protein Data Bank
[17]:
(i) The structure was solved by either X-ray crystallography
or NMR spectroscopy.
(ii) Structures solved by X-ray crystallography have a
resolution better than 3A ˚.
(iii) The protein sequence contains more than 50 amino acids.
(iv) The source organism is human.
(v) The protein target is an enzyme as indicated by the
presence of an Enzyme Commission (EC) number [59].
(vi) The protein has a KEGG annotation [16].
The set of proteins was clustered using the BLASTclust
algorithm [60] removing redundant structures sharing more than
90% sequence similarity over 90% of the sequence length. Finally,
all selected structures were striped of ligands and salts. This results
in set of 830 protein targets (Table S5).
Human pathways. We used the KEGG database [16] to
build a set of human pathways and their corresponding known
protein structures. The 830 protein receptors represent 176
KEGG pathways (Table S4).
Side-effects. A list of drugs and their corresponding ADRs
was obtained from the SIDER database [15] (version 2009-06-19).
In order to deal with similar ADRs that appear under slightly
different names in the SIDER database, we first stemmed all ADR
phrases (extracting the base part of a word or phrase) using the
WordNet lexical database [61]. Then, we measured the
Levenshtein distance [62] between all pairs (the minimal
number of single character edit operations required to transform
one term to the other) and grouped ADRs with an edit distance
smaller than two. For a given drug, we removed an ADR if any of
the following were satisfied:
(i) The ADR has a ‘‘post-marketing’’ label (i.e., the ADR was
only reported after the drug’s approval).
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(iii) The ADR is associated with fewer than 3 drugs or is associated
with more than 5% (approximately 36) of the drugs.
This procedure yielded a set of 506 ADRs (Table S6). Following
Fliri et al. [4] we discard the frequency information of the selected
ADRs and regard their occurrence as binary.
Docking
Automatic docking, while generally less successful than expert
guided docking, has recently shown to be viable for a large diverse
set of receptors [63]. For every protein target we first identify its two
largest pockets using LIGSITE
csc [64]. It has been suggested that in
proteins having known binding sites, in 80.9% of the cases the
largest pocket is the binding site and in 92.7% of the cases the
binding site is one of the two largest ones [65]. Therefore, we dock
each ligand into the two largest pockets using the eHiTS docking
algorithm [56] (Version 6.2). The docking is performed with full
ligand flexibility, examination of all possible protonation states, and
a clipping box of 15A ˚ around the center of the binding pocket. All
other parameters assume their default values. The docking score for
each drug-target pair is the better of the two pocket docking
attempts. Since docking scores may scale differently when using
multiple receptors, we use the z-score to normalize the docking
results. Finally, we use the docking results to generate a list of drug-
target pairs where for a given pair the drug is expected to bind and
influence the protein target. For each drug, we sort the docking
results and keep only those proteins where the docking score was
better than one standard deviation above the mean. This results in
retaining only the top scoring drug-protein pairs for each drug.
Inference Method
We use logistic regression to study the relations between drug-
activated pathways and ADRs (Figure 1). All putative drug-
pathway interactions are inferred by protein-ligand docking. The
drug-pathway interaction is the sum of docking scores over all
proteins belonging to the pathway. These putative interaction
scores are then combined with drug-ADR observations to generate
candidate pathway-ADR associations.
Statistically significant associations are selected using two phases of
logistic regression. In phase one, we perform a logistic regression
between the drug-pathway interactions and the drug’s observed
ADRs. To perform logistic regression, we utilized the L1-regularized
logistic regression code of Kim et al. [19]. The regularization
parameter, l, restricts the number of non-zero weights. The
likelihood of over-fitting is minimized because only those features
having the strongest evidence in the data can have non-zero weights.
We use a relative regularization parameter, l~0:5l0,w h e r el0 is the
smallest regularization value that yields all-zero regression coeffi-
cients. In phase two, the pathway-ADR associations having non-zero
weights were passed through a second logistic regression to determine
their statistical significance. This process included the forward-
selection backward-elimination method for variable selection, the
AIC model selection criteria [66], and the Benjamini-Hochberg
multiple testing correction method [67] with a false discovery rate of
2%. All phase two statistical tests were used as implemented in the R
programming environment (http://www.r-project.org).
Supporting Information
Table S1 The 32 associations supported by the literature. (Top)
The 22 associations with stronger support. (Bottom) The 10
associations with moderate support. (References appear in File S2.)
Found at: doi:10.1371/journal.pone.0012063.s001 (0.09 MB EPS)
Table S2 Parkinson’s related drugs classified as nervous-system
agents according to the ATC classifications.
Found at: doi:10.1371/journal.pone.0012063.s002 (0.04 MB
RTF)
Table S3 The 185 associations inferred by the model.
Found at: doi:10.1371/journal.pone.0012063.s003 (0.16 MB
RTF)
Table S4 176 pathways used in this work.
Found at: doi:10.1371/journal.pone.0012063.s004 (0.09 MB
RTF)
Table S5 830 protein structures used in this work.
Found at: doi:10.1371/journal.pone.0012063.s005 (0.28 MB
RTF)
Table S6 506 ADRs used in this work.
Found at: doi:10.1371/journal.pone.0012063.s006 (0.23 MB
RTF)
Table S7 730 drugs used in this work.
Found at: doi:10.1371/journal.pone.0012063.s007 (0.25 MB
RTF)
Table S8 Normalized scores of drug-primary-target pairs in our
dataset. Pairs were selected using the DrugBank database [4]
(references appear in File S2).
Found at: doi:10.1371/journal.pone.0012063.s008 (0.07 MB EPS)
Table S9 The 32 associations supported by the literature with
the corresponding drug names. (Top) The 22 associations with
stronger support. (Bottom) The 10 associations with moderate
support.
Found at: doi:10.1371/journal.pone.0012063.s009 (0.06 MB
RTF)
Figure S1 Drugs listing tuberculosis, herpes-zoster, and menin-
gitis as ones of their ADRs. The illustration demonstrates the
degree of overlap in which drugs coincide with more than one of
the three bacterial/viral-related ADRs. The low overlap suggests
that inferences of the associations between the three related ADRs
and the GAG degradation pathway were highly independent of
each other. Node and edge representation is the same as Figure 1.
Found at: doi:10.1371/journal.pone.0012063.s010 (0.28 MB EPS)
Figure S2 Drugs listing osteoporosis and aseptic necrosis as ones
of their ADRs. The illustration demonstrates the degree of overlap
in which drugs coincide with more than one of the three bacterial/
viral-related ADRs. The low overlap suggests that inferences of the
associations between the three related ADRs and the type-II
diabetes mellitus pathway were mostly independent of each other.
Node and edge representation is the same as Figure 1.
Found at: doi:10.1371/journal.pone.0012063.s011 (6.29 MB EPS)
Figure S3 Drugs listing fibrosis, cirrhosis, and ascites as ones of
their ADRs. The illustration demonstrates the degree of overlap in
which drugs coincide with more than one of the three bacterial/
viral-related ADRs. The low overlap suggests that inferences of the
associations between the three related ADRs and the NAD
metabolism pathway were highly independent of each other. Node
and edge representation is the same as Figure 1.
Found at: doi:10.1371/journal.pone.0012063.s012 (5.61 MB EPS)
Figure S4 Ranking benchmark of eHiTS [1] and AutoDock-
Vina [2] docking algorithms using the DUD benchmark set [3]
(references appear in File S2).
Found at: doi:10.1371/journal.pone.0012063.s013 (0.19 MB EPS)
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